Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Androgens

Hormones

Prolactin Release-Inhibiting Factors

Androgen Antagonists

Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.

Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.

Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease

Non-invasive assessment of left ventricle structure and function

Transthoracic Echocardiography

Continuously monitored for 5-30 minutes via finger photoplethysmography

Arterial blood pressure

Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer

Submaximal Exercise

Carl J Ade, PhD

The aim of this project is to determine whether androgen deprivation therapy (ADT) decreases left ventricular function in prostate cancer patients. If found successful, this may lead to improved cardiovascular health via treatment and/or lifestyle interventions in prostate cancer populations.

Prostate Cancer is the second most common cancer among American men. Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime. In prostate cancer patients alone, hypotestosteronemia, caused by prostate cancer treatment is associated with visceral adiposity, insulin resistance, metabolic syndrome, decreased high-density lipoprotein, increased low-density lipoprotein, increased triglycerides, loss of muscle mass, erectile disfunction, and a loss of microvascular endothelial function. Recently, several population-based studies have reported an association between androgen deprivation therapy and an increased risk of cardiovascular events, that include myocardial infarction and cardiovascular mortality. Given this link and the growing evidence that androgen-deprivation therapy adversely affects traditional risk factors, it is essential to better understand the role this type of treatment has on cardiac structure and function. As such, the manifestation of cardiovascular toxicities with prostate cancer treatment will initially be subclinical (left ventricular function changes in asymptomatic individuals) compared to clinical (including coronary symptoms or heart failure) and may develop subacutely (during treatment) or chronically.

Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer

Effect of Androgen Deprivation Therapy on Left Ventricular Function in Prostate Cancer Patients and Survivors

measure of left ventricular systolic function

measure of left ventricular systolic and diastolic function

measure of cardiac function at rest and during submaximal exercise

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer	NCT03275181	Prostate Cancer	Transthoracic E... Arterial blood ... Submaximal Exer...	21 Years - 80 Years	Kansas State University
Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer	NCT03275181	Prostate Cancer	Transthoracic E... Arterial blood ... Submaximal Exer...	21 Years - 80 Years	Kansas State University

Spots Global Cancer Trial Database for submaximal exercise